9th International Electronic Conference on Medicinal Chemistry
1–30 Nov 2023
Medicinal Chemistry, Pharmaceuticals, drug
- Go to the Sessions
-
- S1. Opening session
- S2. Invited lectures
- S3. General
- S4. New Small molecules as drug candidates
- S5. Natural Products and Biopharmaceuticals
- S6. Novel and Sustainable approaches in Medicinal Chemistry
- S7. Emerging technologies in drug discovery
- S8. Radiopharmaceuticals
- S9. Drug disposition and drug formulation
- Event Details
The ECMC 2023 is closed!
Thank you for your participation.
The winners of the ECMC 2023 awards will be announced in the first quarter of 2024.
Participants of this conference are cordially invited to contribute a full manuscript to a dedicated Special Issue in the journal Pharmaceuticals (ISSN 1424-8247, IF 4.6). Papers presented at the conference will be granted a 20% discount in the Special Issue.
Welcome from the Chairs
Following the great success of the previous editions, we are pleased to cordially invite you to join us at the 9th International Electronic Conference on Medicinal Chemistry, sponsored by the MDPI open access journal Pharmaceuticals. This platform seeks to provide a discussion forum for scientists from all over the world for recent developments and innovative ideas in medicinal chemistry. This will give students, researchers, and experts the opportunity to share their latest theories, results, models, and applications in this multidisciplinary area of knowledge. This is an entirely online conference that will be held during the month of November at https://ecmc2023.sciforum.net/. No registration fee will be charged to participants, and there is the added advantage that there will be no cost of flights, hotels, etc.
The conference will be organized around the aims and scope of the journal Pharmaceuticals, which includes the following general topics:
Small molecules as drug candidates
Biomolecules, natural products, phages, and cells as therapeutic tools
Biological targets and biomarkers
Radiopharmaceutical sciences, radiochemistry, (hybrid) imaging, and nuclear medicine
Pharmacokinetics and pharmacodynamics
Pharmaceutical preparations and drug delivery
The format of the conference is as follows. Researchers are invited to provide a short abstract (250 words maximum without figures and without references) online at https://sciforum.net/user/submission/create/905 from now until 24 September 2023. Each participant can submit only one abstract as a presenting author and a maximum of three submissions per research group. The authors will be notified in October 2023 with regards to the acceptance status of their abstract, and at which point they will be asked to present their work (in English) in the form of a poster, a slideshow, or a video using the templates provided by the conference (see Instructions for Authors). All accepted submissions will be displayed online, and will be open for discussion, comments, and questions during the entire conference at https://sciforum.net/event/ECMC2023 on 1–30 November 2023.
All participants will be invited to submit a full paper describing their work, which would be peer reviewed and, upon acceptance, published in a Special Issue which is covering the event by templates provided by the conference (see Instructions for Authors). A 20% discount on the article processing charge will be applied.
The most outstanding works, as selected by the scientific committee, will be rewarded with grants offered by the sponsoring journal Pharmaceuticals.
We look forward to engaging in exciting discussions and hearing new ideas and perspectives from experts in the field. All participants are welcome to join the online conference.
Kind regards,
Dr. Alfredo Berzal-Herranz
Prof. Dr. Maria Emília Sousa
Important: Please kindly note that this conference has no registration fees.
Event Chairs
Department of Molecular Biology, Instituto de Parasitología y Biomedicina López-Neyra, (IPBLN-CSIC), Spain
Laboratório de Química Orgânica e Farmacêutica, Departamento de Ciências, Químicas, Faculdade de Farmácia, Universidade do Porto, Portugal
Event Committee
Departamento de Química e Bioquímica (DQB) and Centro de
Química Estrutural (CQE), Institute of Molecular Sciences, Faculdade de Ciências, Universidade de
Lisboa, Portugal
Department of Pharmacy, “G. d’Annunzio” University of
Chieti-Pescara, Italy
Department of Pharmacognosy, Faculty of Pharmacy, Gazi University, Türkiye
Centro de Química Estrutural, Institute of Molecular Sciences, Instituto Superior Técnico, Universidade de Lisboa, Portugal
Center of Health Sciences, IPPN, Laboratory of Molecular Modeling and Computational Structural Biology, Federal University of Rio de Janeiro, Brazil
Department of Pharmacy, University of Naples Federico II, Naples, Italy
Department of Biomolecular Sciences, University of Urbino Carlo Bo, Piazza del Rinascimento 6, Urbino Italy
Department of Molecular Biology, Instituto de Parasitología y Biomedicina López-Neyra (IPBLN-CSIC), PTS Granada, Av. Conocimiento, Granada, Spain
Department of Environmental Biology, Sapienza University of
Rome, Rome, Italy
Helmholtz-Zentrum Dresden-Rossendorf (HZDR) e.V., Institute of Radiopharmaceutical Cancer Research, Germany
School of Pharmacy and Pharmaceutical Sciences, Trinity
Biomedical Sciences Institute, Trinity College Dublin, Ireland
Foodborne Toxin Detection and Prevention Research Unit, Western Regional Research Center, USDA‐ARS, USA
Department of Pharmacy, University of Chieti, Italy
Westfälische Wilhelms-Universität, Institute of Pharmaceutical and Medicinal Chemistry, PharmaCampus, Germany
UCIBIO/REQUIMTE, MedTech-Laboratory of Pharmaceutical
Technology, Department of Drug Sciences, Faculty of Pharmacy, University of Porto, Portugal
Univ Rouen Normandie, CNRS UMR 6014 COBRA, F-76000 Rouen, France
State Key Laboratory of Genetic Engineering and Engineering Research Center of Gene Technology (Ministry of Education), School of Life Sciences, Zhongshan Hospital, Fudan University, Shanghai 200438, China
Faculté de Pharmacie, Université Libre de Bruxelles, Brussels, Belgium
Laboratório de Avaliação e Síntese de Substâncias Bioativas (LASSBio), Instituto de Ciências Biomédicas, Universidade Federal do Rio de Janeiro, Brazil,
Programa de Pós-Graduação em Farmacologia e Química Medicinal, Instituto de Ciências Biomédicas, Universidade Federal do Rio de Janeiro, Brazil
Invited Speakers
Department of Pharmacy University of Naples Federico II, Naples Italy
Laboratory of Organic and Pharmaceutical Chemistry, Department of Chemical Sciences, Faculty of Pharmacy, University of Porto, Portugal,
CIIMAR—Interdisciplinary Centre of Marine and Environmental Research, University of Porto, Portugal
Department of Pharmacy, “G. d’Annunzio” University of Chieti-Pescara, Italy
Werner Siemens Imaging Center, Department of Preclinical Imaging and Radiopharmacy, Eberhard Karls University Tübingen
Institute of Pharmaceutical and Medicinal Chemistry, University of Münster
School of Biochemistry & Immunology, Trinity Biomedical Sciences Institute, Trinity College Dublin, Ireland
Nuclear Research Center, University of the Republic, Uruguay
Department of Pharmacy, University of Chieti, Italy
Instituto de Parasitología y Biomedicina López Neyra, CSIC
Institute of Radiopharmaceutical Cancer Research, Helmholtz-Zentrum Dresden-Rossendorf
Department of Environmental Biology, Sapienza University of Rome, Rome, Italy
Sessions
S2. Invited lectures
S3. General
S4. New Small molecules as drug candidates
S5. Natural Products and Biopharmaceuticals
S6. Novel and Sustainable approaches in Medicinal Chemistry
S7. Emerging technologies in drug discovery
S8. Radiopharmaceuticals
S9. Drug disposition and drug formulation
List of accepted submissions (218)
Id | Title | Authors | Presentation Video | Poster PDF | |||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
sciforum-083493 | Targeting conserved protein binding sites on SARS-CoV-2: nsp3 case study | , | N/A |
Show Abstract |
|||||||||||||||||||||||||||||||||||||
As new medications are used to treat COVID-19, many studies have reported that proteins such as spike, polymerase and proteases are prone to high levels of mutation that can create resistance to therapy over time [1]. Thus, it becomes necessary to, not only target other viral proteins such as the non-structural proteins (nsp’s), but to also target the most conserved residues of these proteins. A synergistic combination of bioinformatics, computer-aided drug-design and in vitro studies can feed into better understanding of SARS-CoV-2 (SC-2) and therefore help in the development of small molecule inhibitors against the nsp’s. As part of our initial anti-viral work, a pharmacophore study on nsp15 found a hit molecule (INS316) that made interactions with Ser293, Lys344 and Leu345 residues [2] which are highly conserved across SC-2. We have performed multiple sequence alignment studies on different datasets i.e., ~200,000, ~1 million and ~11 million sequences of SC-2 Orf1ab sequences to identify the most conserved residues. These residues were then visualized on 3D protein X-ray structures using MOE software. We found that there were known and novel binding pocket residues that were 100% conserved in our datasets. Our results indicate that these highly conserved pockets can be targeted for developing promising SC-2 inhibitors. We have also performed mutational analysis and have found different mutational hotspots across the nsp’s. Our group has recently been selected to enter two international challenges organized by the CACHE consortium to discover inhibitors of the RNA binding tunnel of SC-2 nsp13 and the Mac1 domain of SC-2 nsp3. We have used a tiered screening workflow which included the use of volume/shape information of the binding pockets (fastROCS), use of in-house pharmacophore generation software (MoPBS [3]/MOE) and performed docking in the binding pocket (FRED) to rank hits for subsequent clustering and to identify compounds that bind to these conserved pockets. Our results on nsp3 will be presented here. References
|
|||||||||||||||||||||||||||||||||||||||||
sciforum-082578 |
Thioglycosides as vectors for G-quadruplex ligands: potent anticancer and antiparasitic drugs
Efres Belmonte-Reche ,
,
Marta Martínez-García ,
Michela Zuffo ,
Aurore Guedin ,
Adriana Stucchi ,
,
María Cabello-Donayre ,
,
Jean Louis Mergny ,
,
Submitted: 11 Oct 2023 Abstract: Show Abstract |
Efres Belmonte-Reche ,
,
Marta Martínez-García ,
Michela Zuffo ,
Aurore Guedin ,
Adriana Stucchi ,
,
María Cabello-Donayre ,
,
Jean Louis Mergny ,
,
|
N/A |
Show Abstract |
|||||||||||||||||||||||||||||||||||||
G-quadruplexes (G4) are DNA secondary structures that play important roles in the regulation of gene expression in human cells and have been proposed as therapeutic targets in cancer. At the same time, putative G-quadruplex forming sequences have also been found on the genome of parasites T. brucei, L. major and P. falciparum suggesting they could also be explored as therapeutic targets. We have designed and prepared thio sugars as vectors for naphthalene diimides, a classical G-quadruplex ligand, aiming to improve binding to G4 and biostability. Recent results on their efficacy against cancer cells and parasitic infections will be presented. |
|||||||||||||||||||||||||||||||||||||||||
sciforum-082515 | Colloidal Silver Nanoparticles Obtained via Radiolysis: Synthesis Optimization and Antibacterial Properties |
,
,
,
Aisara Amanova ,
,
,
Hynd Remita ,
|
N/A | N/A |
Show Abstract |
||||||||||||||||||||||||||||||||||||
Silver nanoparticles (AgNPs) with broad-spectrum antimicrobial properties are gaining increasing interest in fighting multidrug-resistant bacteria. Herein we describe the synthesis of AgNPs stabilized by polyvinyl alcohol (PVA) with high purity and homogeneous sizes using radiolysis. Solvated electrons and reducing radicals are induced from solvent radiolysis and no other chemical reducing agents are needed to reduce the metal ions. Another advantage of this method is that it leads to sterile colloidal suspensions, which can be directly used for medical applications. We systematically investigated the effect of the silver salt precursor on the optical properties, particle size and morphology of the resulting colloidal AgNPs. With Ag2SO4 precursor, the AgNPs displayed a narrow size distribution (20 ± 2 nm). In contrast, AgNO3 and AgClO4 precursors lead to inhomogeneous AgNPs of various shapes. Moreover, the optimized AgNPs synthesized from Ag2SO4 were stable upon storage in water and phosphate-buffered saline (PBS) and were effective in inhibiting the growth of Staphylococcus. aureus (S. aureus) at a concentration of 0.6 μg·mL−1 and completely eradicated it at a concentration of 5.6 μg·mL−1. When compared with various conventional methods and other different strategies, the remarkable bactericidal ability against S. aureus of the AgNPs produced here opens up new avenues for further applications in medicine and other domains. |
|||||||||||||||||||||||||||||||||||||||||
sciforum-081520 | Mucoadhesive polymer coated MXene as a carrier for the delivery of antimicrobial drugs. | , | N/A |
Show Abstract |
|||||||||||||||||||||||||||||||||||||
Abstract: MXene are a group of two-dimensional (2D) transition metal carbides and carbonitrides. MXene have a wide range of uses in biotechnology, drug delivery, and bioimaging. Due to their biocompatibility and excellent antimicrobial activities, these two-dimensional (2D) nanomaterials have gained significant attention. MXene are one of these nanomaterials that demonstrated excellent bactericidal, fungicidal activity, and antimicrobial characteristics. Luliconazole drug are a highly effective antifungal drug in vitro against dermatophytes. However, luliconazole drugs suffers from less stability, poor solubility, low permeability, rapid metabolism, and rapid elimination from the topical area of the skin. For the improvement of drug stability, skin permeability, and efficacy, these drugs were loaded onto MXene nanocarriers, and for adhesion to the skin, drug-loaded MXene was coated with a mucoadhesive polymer. Sulphur-containing amino acids present in epithelial cells formed strong Di-sulphide bonds with thiolate pullulan polymer and adhered strongly. The poor bioavailable luliconazole-loaded nanocarrier showed sub-therapeutic effects because a major portion of the dose never reached the targeted sites. Thus, the purpose of our study was to improve the antimicrobial activity of the particular drug while lowering the dose, dose frequency, ensuring high stability, and delivering it to the targeted site. Many studies had been conducted to increase the bioavailability of badly absorbed antimicrobial drugs to enhance their clinical efficacies. Drug-loaded MXene nanocarriers were synthesized by incubating the drug with the MXene dispersion method. Drug-loaded MXene nanocarriers were characterized by different techniques such as ATR-FTIR, DSC, TGA, XRD, HR-TEM, NMR, and DLS. In this research work, thiolate polymer-coated drug-loaded MXene was synthesized and evaluated for its application as a carrier for the delivery of antimicrobial drugs. |
|||||||||||||||||||||||||||||||||||||||||
sciforum-081982 | Chronic exposure to the antidepressant paroxetine disrupts fitness-related behaviours in fish |
,
,
,
,
Peter Kille ,
|
N/A |
Show Abstract |
|||||||||||||||||||||||||||||||||||||
The environmental levels of paroxetine (PAR), a selective serotonin reuptake inhibitor antidepressant, have risen due to increased consumption combined with the inefficiency of wastewater treatment removal. The functional conservation of important SSRI targets in vertebrates raises concerns about the potential adverse effects of exposure to pharmaceutically active molecules, such as PAR, on non-target organisms. This study addressed the effects of PAR chronic exposure (21-days) on adult zebrafish, assessing the effects of a low (40 µg/L - environmentally relevant concentration) and a high (400 µg/L – worst-case scenario) concentration in fish swimming behaviour and stress response. PAR-exposed fish displayed reduced swimming activity, stress response impairment and disruption of thigmotactic behaviour. These PAR-induced behavioural modifications may directly influence animal fitness, which, in turn, may lead to population and community disruption. |
Instructions for Authors
Submission should be completed online by the authors by registering with https://sciforum.net/ and using the “Start New Submission” function once logged into the system.
- Scholars interested in participating in the conference can submit their abstract (250 words maximum without figures and without references) online at this website until 24 September 2023
- Based on the submitted abstract, the conference committee will conduct a pre-evaluation of whether a contribution from the authors of the abstract will be welcome for 8th International Electronic Conference on Medicinal Chemistry. All authors will be notified by 1 October 2023 with regard to the acceptance status of their abstract.
- If the abstract is accepted for this conference, the author will be invited to prepare a full description of their work in the form of a poster, slideshow, or video at their best convenience, until the submission deadline of 12 October 2023.
- Posters must be uploaded as a PDF file using the Poster_template.pptx file available at the end of this section.
- Slideshows must be uploaded as a PDF file using the PPT_template.pptx file available at the end of this section.
- Flash communications (5 minutes) and communications (10-20 minutes) must be uploaded as an mp4/.webm/.ogg (max size: 250Mb) file (video) using the PPT_template.pptx file available at the end of this section.
- Tips for authors: if you would like to prepare a video based on your PowerPoint presentation, you may use the "record slide" function in PowerPoint.
This must be uploaded before 12 October 2023, for a final check and approval. Each work will be directed to the appropriate panel (posters, slideshows, flash communications, communications) by the Conference Office.
Contributions will be displayed on the website using Sciforum.net’s proprietary slides viewer and will be accessible at https://sciforum.net/event/ECMC2023 at the time of the conference. They can be prepared in exactly the same way as for any traditional conference where research results can be presented. Contributions must be converted to PDF format before submission, so that they can be easily and automatically converted to be displayed online. The organization of posters is left completely up to the authors, provided that they use the conference’s template.
Certificate of Attendance : After the event, the participants of ECMC 2023 will be able to download an electronic Certificate of Attendance by logging in to your Sciforum personal account. Once you are logged-in, go to your profile and click on 'My certificates'. A list of all Sciforum events you have attended is available and you simply have to click on "Download" next to the correct event.
We recommend the following organization for your slideshow, poster or video, using the Conference’s template:
Slides- Length of the presentation: no more than 30 slides
- Slides can be prepared the same way as for any traditional conference. They should be converted into a PDF format before submission.
- Slide 1 (strictly one slide): Title, authors’ names, affiliation(s), email address of corresponding author, logos of the laboratory and/or institution (not mandatory).
- Slide 2 (strictly one slide): Graphical abstract; repeat the title of the presentation but avoid other text as far as possible.
- Slide 3 (strictly one slide): Abstract (max. 250 words) and 3–5 keywords, separated by semicolons.
- Slide 4 and following slides: These should contain (in the given sequence) Introduction, Results and Discussion, Conclusions.
- Last slide: Acknowledgments, and logos of sponsors (not mandatory).
Posters
Posters will be available on this conference website during and after the event. Like papers presented on the conference, participants will be able to ask questions and make comments about the posters. Posters can be presented without an accompanying proceedings paper.
The poster should be in PDF format
- The minimum size for images is 148 mm × 210 mm (horizontal × vertical) at 300 dpi.
- The content of the poster should be a comprehensive presentation of your accepted submission.
- No copyright issues with any elements in the poster.
Event Awards
To acknowledge the support of the conference’s esteemed authors and recognize their outstanding scientific accomplishments, we are pleased to announce that the conference will provide one Best Poster Award, one Best Slideshow Award, one Best Flash Communication Award,one Best Communication Award, one Best Invited Lecturer Award, and one One-Day Microwave Practice/Test.
All submissions will be considered, independently of the session (general and round table). The best works will be selected by the members of the Scientific Committee.
Winner Announcement:
On behalf of the chairs of ECMC2023, we are pleased to announce the winners.
The Best Poster Award have been awarded to
- sciforum-081497, "A novel fluorescent labeling compound for GluN2A containing N-methyl-D-aspartate receptors identified by Autodisplay of GluN1/GluN2A ligand binding domains", Alexander Dombovski, Ruben Steigerwald, Nadine Ritter, Paul Disse, Gunnar Goerges, Jana Osthues, Isabel Aymanns, Carina Dilkaute, Julian Schreiber, Martina Düfer, Guiscard Seebohm, Bernhard Wünsch, Joachim Jose.
The Best Slideshow Award have been awarded to
- sciforum-081134, "Novel Atorvastatin loaded peptide amphiphiles for corneal neovascularization", Elena Sánchez López, Maria José Gómara, Isabel Haro.
The Best Flash Communication Award have been awarded to
- sciforum-075304, "Coaxial wet-spun fibers loaded with essential oils for the treatment of chronic wounds", Catarina S. Miranda, Elina Marinho, Susana P. G. Costa, Natália C. Homem, Helena P. Felgueiras.
The Best Communication Award have been awarded to
- sciforum-081260, "Adarotene-related retinoids as potential antimicrobial agents against multidrug-resistant gram-positive strains", Salvatore Princiotto, Loana Musso, Francesca Sacchi, Lucia Magnani, Maria Luisa Mangoni, Claudio Pisano, Mattia Mori, Sabrina Dallavalle.
The Best Invited Lecturer Award have been awarded to
- sciforum-081230, "Development of radiotracers for molecular imaging and detection of tumour-associated matrix-modifying enzymes", Reik Löser.
The One-Day Microwave Practice/Test have been awarded to
- sciforum-081282, "Green synthesis, antimicrobial and cytotoxic effects of silver nanoparticles mediated by Eucalyptus camaldulensis leaf extract", Afrah Mohammed, Reham Aldahasi.
The Awards
Number of Awards Available: 1
The open access peer-reviewed Journal Pharmaceuticals will offer a reward of 400 CHF to the participant with the Best Poster.
Number of Awards Available: 1
The open access peer-reviewed Journal Pharmaceuticals will offer a reward of 400 CHF to the participant with the best slideshow.
Number of Awards Available: 1
The open access peer-reviewed Journal Pharmaceuticals will offer a reward of 400 CHF to the participant with the Best Flash Communication.
Number of Awards Available: 1
The open access peer-reviewed Journal Pharmaceuticals will offer a reward of 400 CHF to the participant with the Best Communication.
Number of Awards Available: 1
The open access peer-reviewed Journal Pharmaceuticals will offer a reward of 500 CHF to Best Invited Lecturer.
Number of Awards Available: 1
One Day Microwave Practice/Test for free offered by Microwave Technologies Consulting. Selection will be made by the Company following strict scientific criteria.
Conference Secretariat
Mr. Duke Wang
Ms. Jennifer Wang
Ms. Ann Li
Email: ecmc@mdpi.com
S1. Opening session
Session Chairs
Dr. Alfredo Berzal-Herranz, Department of Molecular Biology, Instituto de Parasitología y Biomedicina López-Neyra, (IPBLN-CSIC), Spain
Prof. Dr. Maria Emília Sousa, Laboratório de Química Orgânica e Farmacêutica, Departamento de Ciências, Químicas, Faculdade de Farmácia, Universidade do Porto, Portugal
S2. Invited lectures
Session Chairs
Prof. Dr. Maria Emília Sousa, Laboratório de Química Orgânica e Farmacêutica, Departamento de Ciências, Químicas, Faculdade de Farmácia, Universidade do Porto, Portugal
Dr. Alfredo Berzal-Herranz, Department of Molecular Biology, Instituto de Parasitología y Biomedicina López-Neyra, (IPBLN-CSIC), Spain
Show all published submissions (10) Hide published submissions (10)
Submissions
List of Papers (10) Toggle list
S3. General
Session Chair
Dr. Jong Heon Kim, Foodborne Toxin Detection and Prevention Research Unit, Western Regional Research Center, USDA‐ARS, USA
Show all published submissions (42) Hide published submissions (42)
Submissions
List of Papers (42) Toggle list
S4. New Small molecules as drug candidates
Session Chairs
Prof. Dr. Mary J. Meegan, School of Pharmacy and Pharmaceutical Sciences, Trinity Biomedical Sciences Institute, Trinity College Dublin, Ireland
Dr. Andrea Duranti, Department of Biomolecular Sciences, University of Urbino Carlo Bo, Piazza del Rinascimento 6, Urbino Italy
Show all published submissions (67) Hide published submissions (67)
Submissions
List of Papers (67) Toggle list
S5. Natural Products and Biopharmaceuticals
Session Chairs
Prof. Dr. Daniela De Vita, Department of Environmental Biology, Sapienza University of Rome, Rome, Italy
Dr. Cristina Romero-López, Department of Molecular Biology, Instituto de Parasitología y Biomedicina López-Neyra (IPBLN-CSIC), PTS Granada, Av. Conocimiento, Granada, Spain
Show all published submissions (53) Hide published submissions (53)
Submissions
List of Papers (53) Toggle list
S6. Novel and Sustainable approaches in Medicinal Chemistry
Session Chairs
Prof. Dr. Joachim Jose, Westfälische Wilhelms-Universität, Institute of Pharmaceutical and Medicinal Chemistry, PharmaCampus, Germany
Prof. Dr. Maria Matilde Soares Duarte Marques, Centro de Química Estrutural, Institute of Molecular Sciences, Instituto Superior Técnico, Universidade de Lisboa, Portugal
Show all published submissions (14) Hide published submissions (14)
Submissions
List of Papers (14) Toggle list
S7. Emerging technologies in drug discovery
Session Chairs
Prof. Dr. Osvaldo Andrade Santos-Filho, Center of Health Sciences, IPPN, Laboratory of Molecular Modeling and Computational Structural Biology, Federal University of Rio de Janeiro, Brazil
Dr. Marialuigia Fantacuzzi, Department of Pharmacy, “G. d’Annunzio” University of Chieti-Pescara, Italy
Show all published submissions (15) Hide published submissions (15)
Submissions
List of Papers (15) Toggle list
S9. Drug disposition and drug formulation
Session Chair
Dr. Isabel Martins De Almeida, UCIBIO/REQUIMTE, MedTech-Laboratory of Pharmaceutical Technology, Department of Drug Sciences, Faculty of Pharmacy, University of Porto, Portugal
Show all published submissions (17) Hide published submissions (17)
Submissions
List of Papers (17) Toggle list